Maze Therapeutics (NASDAQ:MAZE) Shares Down 6.8% – Here’s What Happened

Maze Therapeutics, Inc. (NASDAQ:MAZE) shares fell 6.8% during trading on Monday . The stock traded as low as $26.42 and last traded at $26.71. Approximately 388,599 shares traded hands during trading, a decline of 42% from the average daily volume of 669,093 shares. The stock had previously closed at $28.65.

Wall Street Analyst Weigh In

MAZE has been the subject of several recent research reports. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday. Truist Financial reduced their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Price Performance

The firm has a market cap of $1.52 billion, a P/E ratio of -10.86 and a beta of 2.21. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The business’s 50 day moving average is $27.63 and its two-hundred day moving average is $33.32.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). As a group, analysts anticipate that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Insider Activity

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the completion of the sale, the insider directly owned 26,250 shares in the company, valued at approximately $717,675. The trade was a 22.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $26.22, for a total value of $393,300.00. Following the completion of the transaction, the chief marketing officer directly owned 15,000 shares in the company, valued at approximately $393,300. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 141,470 shares of company stock valued at $3,902,714 in the last ninety days. 5.30% of the stock is owned by company insiders.

Institutional Trading of Maze Therapeutics

Several large investors have recently modified their holdings of the stock. Royal Bank of Canada lifted its position in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Maze Therapeutics in the 4th quarter worth $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics in the 4th quarter valued at $43,000. California State Teachers Retirement System grew its position in Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after purchasing an additional 766 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Maze Therapeutics during the 2nd quarter valued at $48,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.